OrganiGram Holdings Inc.
TSX:OGI.TODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $135.37M
- Beta
- 1.84
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$0.19
Volume 0.54M
Average 0.19M
Returns on capital
OrganiGram Holdings Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-7.1%
avg -18.3%
ROIC
-13.0%
avg -16.5%
ROA
-4.4%
avg -15.1%
Analysis
ROA is currently the strongest return metric at -4.4% versus its period average of -15.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
James H. Yamanaka | Chief Executive Officer & Director | CAD 761.3K | 58 | — | — |
Timothy Emberg | President of Organigram Canada | CAD 464.92K | — | — | — |
Greg Guyatt | Chief Financial Officer | CAD 464.8K | — | — | — |
Helen Martin | Chief Legal Officer & Corporate Secretary | CAD 462.7K | 48 | — | — |
Peter L. Amirault | Executive Chairman | CAD 95K | 65 | — | — |
Max Schwartz | Director of Investor Relations | — | — | — | — |
Megan Amber McCrae | Senior Vice President of Corporate Strategy & International Growth | — | — | — | — |
Valerie Rother | Chief People Officer | — | — | — | — |
Adrian Frenzel | Global Chief Operating Officer | — | — | — | — |
Bradley Gunter | Senior Vice President of Sales | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +21.1% | +16.7% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +21.1% over three years. Forward estimates point to Revenue at +16.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does OrganiGram Holdings Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about OGI.TO's management, answered from reported figures.
Who manages OGI.TO?
OrganiGram Holdings Inc. (OGI.TO) lists 10 active executives. The top listed executive is Max Schwartz, Director of Investor Relations.
Continue the stock analysis
Jump to another research area for this company.